Literature DB >> 14551698

[Mitoxanthrone in the therapy of multiple sclerosis].

B C Kieseier1, R Gold, H-P Hartung.   

Abstract

The recent publication of the MIMS study (Mitoxantrone in multiple sclerosis), approval by local health authorities, and the recommendation by the MS Therapy Consensus Group (MSTCG) support the use of mitoxantrone in patients with active multiple sclerosis. This review provides an outline of relevant preclinical and clinical studies, discusses relevant side effects of the compound, and compares its use with other therapeutic approaches to this crippling disorder.

Entities:  

Mesh：

Substances：

Year:  2003        PMID： 14551698     DOI： 10.1007/s00115-003-1566-6

Source DB:  PubMed          Journal:  Nervenarzt        ISSN： 0028-2804            Impact factor:   1.214


  33 in total

1.  Therapy-related acute myelogenous leukaemia (t-AML) in a patient with multiple sclerosis treated with mitoxantrone.

Authors:  C Heesen; M Bruegmann; J Gbdamosi; E Koch; A Mönch; C Buhmann
Journal:  Mult Scler       Date:  2003-03       Impact factor: 6.312

2.  Cardiac adverse effects associated with mitoxantrone (Novantrone) therapy in patients with MS.

Authors:  R G Ghalie; G Edan; M Laurent; E Mauch; S Eisenman; H P Hartung; R E Gonsette; M D Butine; D E Goodkin
Journal:  Neurology       Date:  2002-09-24       Impact factor: 9.910

3.  Mitoxantrone, a topoisomerase II inhibitor, induces apoptosis of B-chronic lymphocytic leukaemia cells.

Authors:  B Bellosillo; D Colomer; G Pons; J Gil
Journal:  Br J Haematol       Date:  1998-01       Impact factor: 6.998

4.  Topoisomerase II is required for mitoxantrone to signal nuclear factor kappa B activation in HL60 cells.

Authors:  M P Boland; K A Fitzgerald; L A O'Neill
Journal:  J Biol Chem       Date:  2000-08-18       Impact factor: 5.157

5.  Suppression of acute and relapsing experimental allergic encephalomyelitis with mitoxantrone.

Authors:  F D Lublin; M Lavasa; C Viti; R L Knobler
Journal:  Clin Immunol Immunopathol       Date:  1987-10

6.  An open-trial evaluation of mitoxantrone in the treatment of progressive MS.

Authors:  J H Noseworthy; M B Hopkins; M K Vandervoort; S J Karlik; D H Lee; M Penman; G P Rice; K D Grinwich; H Cauvier; B J Harris
Journal:  Neurology       Date:  1993-07       Impact factor: 9.910

Review 7.  A study of therapy-related acute leukaemia after mitoxantrone therapy for multiple sclerosis.

Authors:  R G Ghalie; E Mauch; G Edan; H P Hartung; R E Gonsette; S Eisenmann; E Le Page; M D Butine; D E De Goodkin
Journal:  Mult Scler       Date:  2002-10       Impact factor: 6.312

8.  Selective immunomodulation by the antineoplastic agent mitoxantrone. I. Suppression of B lymphocyte function.

Authors:  J M Fidler; S Q DeJoy; J J Gibbons
Journal:  J Immunol       Date:  1986-07-15       Impact factor: 5.422

9.  Treatment of multiple sclerosis with mitoxantrone.

Authors:  E Mauch; H H Kornhuber; H Krapf; U Fetzer; H Laufen
Journal:  Eur Arch Psychiatry Clin Neurosci       Date:  1992       Impact factor: 5.270

10.  Mitoxantrone in progressive multiple sclerosis: a placebo-controlled, double-blind, randomised, multicentre trial.

Authors:  Hans-Peter Hartung; Richard Gonsette; Nikolaus König; Hubert Kwiecinski; Andreas Guseo; Sean P Morrissey; Hilmar Krapf; Thomas Zwingers
Journal:  Lancet       Date:  2002 Dec 21-28       Impact factor: 79.321
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.